Clinical significance of methylenetetrahydrofolate reductase gene polymorphism in children with acute lymphoblastic leukemia receiving protocol therapy

Cover Page

Cite item

Full Text

Abstract

The incidence of methylenetetrahydrofolate reductase ( MTHFR ) gene polymorphism was studied in 97 Belorussian children with acute lymphoblastic leukemia (ALL) treated by the ALL-MB 2002 protocol. It was found that 11 (11.3%) of these patients were homozygous carriers of MTHFR mutant allele 677TT and 14 (14.4%) carried the MTHFR mutant allele 1298CC, which was in line with the incidence of this polymorphism in the European population of children with ALL. Homozygous carriers of MTHFR variant allele 677TT more often developed grade III-IV hepatotoxicity during the consolidation therapy.

About the authors

O. V. Petina

Republican Center of Pediatric Oncology, Hematology, and Immunology

Author for correspondence.
Email: o.vpetina@mail.ru
Russian Federation

A. A. Zborovskaya

Republican Center of Pediatric Oncology, Hematology, and Immunology

Email: zborovskaa@mail.ru
Russian Federation

M. L. Matevosyan

Republican Center of Pediatric Oncology, Hematology, and Immunology

Email: mariam@algimed.by
Russian Federation

T. V. Savitskaya

Republican Center of Pediatric Oncology, Hematology, and Immunology

Email: tat_savitskaya@tut.by
Russian Federation

O. V. Aleinikova

Republican Center of Pediatric Oncology, Hematology, and Immunology

Email: aleinikova2004@mail.ru
Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Petina O.V., Zborovskaya A.A., Matevosyan M.L., Savitskaya T.V., Aleinikova O.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.